Pathways to prescribe Medical Cannabis in Australia
Navigating the pathways to prescribe medicinal cannabis in Australia involves understanding the regulatory frameworks established by the Therapeutic Goods Administration (TGA). Healthcare professionals can access unapproved therapeutic goods, including medicinal cannabis, through mechanisms such as the Special Access Scheme (SAS) and the Authorised Prescriber (AP) pathways. Familiarity with these pathways ensures compliance with federal and regional guidelines, facilitating informed decisions in patient care.
Authorised Prescriber Scheme (AP)
Healthcare professionals can apply to become Authorised Prescribers, allowing them to prescribe specific unapproved medicinal cannabis products to a particular class of patients without seeking individual TGA approvals for each prescription. This streamlines the prescribing process for both practitioners and patients.
Special Access Scheme (SAS)
SAS Category A: This notification pathway allows registered medical practitioners to prescribe unapproved medicinal cannabis products to patients who are seriously ill.
SAS Category B: This application pathway is available to prescribing healthcare practitioners, including medical and nurse practitioners, to access unapproved medicinal cannabis products for individual patients. Each application requires a clinical justification and is assessed by the Therapeutic Goods Administration (TGA) before approval.